Skip to Main Content

Paper Details

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res
23
2017
Author NameAffiliation
Stephen Welch
Shingo SakashitaPrincess Margaret Cancer Centre and University Health Network, University of Toronto
Ming-Sound TsaoPrincess Margaret Cancer Centre and University Health Network, University of Toronto
  • 1 - 3

Datasets

Release 1.2